Tilarginine

Tilarginine

SCHEMBL6370536

CNC(=N)NCCC[C@@H](N)C(=O)O

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NOS1NOS2NOS3

The experimentally established mechanism targets of Tilarginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 known ✓ P35228 5/20 0.46
NOS3 known ✓ P29474 4/20 0.46
NOS1 known ✓ P29475 4/20 0.46
OTC P00480 1/20 0.51
DDAH1 O94760 1/20 0.44
GSR P00390 1/20 0.44
CYP2C19 P33261 2/20 0.41
DPP7 Q9UHL4 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NOD1 Q9Y239 1/20 0.41
ARG2 P78540 4/20 0.41
ARG1 P05089 3/20 0.41
PMP22 Q01453 1/20 0.41
CYP1A2 P05177 2/20 0.40
TSHR P16473 2/20 0.40
CYP3A4 P08684 1/20 0.40
GLA P06280 1/20 0.40
NFKB1 P19838 1/20 0.40
APEX1 P27695 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tilarginine SCHEMBL315843 1.00 OTC (0.51) OTCNOS2NOS3NOS1DDAH1
Tilarginine SCHEMBL12028766 1.00 OTC (0.51) OTCNOS2NOS3NOS1DDAH1
Tilarginine SCHEMBL2229626 0.98 OTC (0.50) OTCNOS2NOS3NOS1DDAH1
Tilarginine SCHEMBL1321022 0.97 OTC (0.49) OTCNOS2NOS3NOS1DDAH1
SCHEMBL1006081 0.95 GSR (0.47) OTCNOS2NOS3NOS1DDAH1
SCHEMBL14423587 0.95 GSR (0.47) OTCNOS2NOS3NOS1DDAH1
SCHEMBL4393876 0.89 PMP22 (0.43) OTCNOS2NOS3NOS1GSR
SCHEMBL29533865 0.89 PMP22 (0.43) OTCNOS2NOS3NOS1GSR
SCHEMBL19608041 0.86 DPP7 (0.41) OTCNOS2NOS3NOS1DDAH1
SCHEMBL12279136 0.86 DPP7 (0.41) OTCNOS2NOS3NOS1DDAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3077129-B1 CLEANING FORMULATION FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MAT USA INC (US) 2020-11-11 EP claimed
US-12275921-B2 Treatment liquid and substrate treatment method FUJIFILM CORPORATION (JP) 2025-04-15 US disclosed
US-20240400949-A1 COMPOSITION, COMPOUND, RESIN, SUBSTRATE TREATMENT METHOD, AND MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE FUJIFILM CORPORATION (JP) 2024-12-05 US disclosed
EP-3719105-B1 CLEANING FORMULATION FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MAT USA INC (US) 2023-09-27 EP disclosed
US-20230287304-A1 TREATMENT LIQUID AND SUBSTRATE TREATMENT METHOD FUJIFILM CORPORATION (JP) 2023-09-14 US disclosed
US-11639487-B2 Cleaning formulation for removing residues on surfaces FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2023-05-02 US disclosed
US-11618867-B2 Cleaning formulation for removing residues on surfaces FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2023-04-04 US disclosed
US-20230100080-A1 CLEANING FORMULATION FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. 2023-03-30 US disclosed
US-20230066300-A1 CLEANING FORMULATION FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. 2023-03-02 US disclosed
US-20220275313-A1 CLEANING FORMULATION FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. 2022-09-01 US disclosed
US-11286444-B2 Cleaning formulation for removing residues on surfaces FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2022-03-29 US disclosed
US-7253194-B2 Compounds and inhibitors of phospholipases THE UNIVERSITY OF QUEENSLAND (AU) 2007-08-07 US disclosed
US-6858396-B2 Positively charged non-natural amino acids, methods of making and using thereof in peptides MEDICAL UNIVERSITY OF SOUTH CAROLINA (US) 2005-02-22 US disclosed
US-6783946-B2 CLOSELY REPLICATE THE NATURAL AMINO ACIDS LYSINE AND ARGININE. MEDICAL UNIVERSITY OF SOUTH CAROLINA 2004-08-31 US disclosed
US-6566330-B1 As chemical intermediate MEDICAL UNIVERSITY OF SOUTH CAROLINA FOUNDATION RESEARCH DEVELOPMENT 2003-05-20 US disclosed
US-20020137730-A1 Positively charged non-natural amino acids, methods of making and using thereof in peptides MEDICAL UNIVERSITY OF SOUTH CAROLINA 2002-09-26 US disclosed
US-20020068701-A1 Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides MEDICAL UNIVERSITY OF SOUTH CAROLINA 2002-06-06 US disclosed
US-6358922-B1 ARGININE DERIVATIVES MEDICAL UNIVERSITY OF SOUTH CAROLINA 2002-03-19 US disclosed
WO-1998017626-A2 POSITIVELY CHARGED NON-NATURAL AMINO ACIDS, METHODS OF MAKING THEREOF, AND USE THEREOF IN PEPTIDES MEDICAL UNIVERSITY OF SOUTH CAROLINA (US) 1998-04-30 WO disclosed
CN-1087624-A Arginine derivative WELLCOME FOUND (GB) 1994-06-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068701-A1 Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides ARGLU1, NGLY1, QPCTL NOS2 447/4885NOS3 322/4885NOS1 617/4885
US-20020137730-A1 Positively charged non-natural amino acids, methods of making and using thereof in peptides NGLY1, LNPEP, DNPEP NOS2 1906/4885NOS3 1450/4885NOS1 2372/4885
US-20240400949-A1 COMPOSITION, COMPOUND, RESIN, SUBSTRATE TREATMENT METHOD, AND MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE RER1, POLG, PWWP2B NOS2 215/4885NOS3 382/4885NOS1 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.